Table 1.
Compound (I, II—First and Second MRM Transitions) | MRM Transition (m/z) | Dwell Time (ms) | Declustering Potential (V) | Entrance Potential (V) | Collision Energy (V) | Collision Cell Exit Potential (V) | Limit of Quantitation (ng/mL) |
---|---|---|---|---|---|---|---|
Apixaban I | 460.1 → 199.1 | 20 | 196 | 10 | 53 | 8 | 0.22 |
Apixaban II | 460.1 → 185.1 | 20 | 196 | 10 | 55 | 12 | 1.06 |
DAB-D3 I | 475.2 → 292.1 | 100 | 146 | 10 | 39 | 18 | - |
DAB-D3 II | 475.2 → 175.1 | 100 | 146 | 10 | 55 | 10 | - |
Dabigatran I | 472.1 → 289.0 | 100 | 126 | 10 | 39 | 6 | 0.57 |
Dabigatran II | 472.1 → 324.1 | 100 | 126 | 10 | 29 | 8 | 1.18 |
Rivaroxaban I | 436.0 → 144.8 | 160 | 156 | 10 | 33 | 18 | 0.79 |
Rivaroxaban II | 436.0 → 231.0 | 160 | 156 | 10 | 29 | 20 | 3.38 |
Abbreviations: DAB-D3, deuterated analogue ofdabigatran; MRM, multiple reaction monitoring.